Background: Biomarkers of stroke are an evolving field of clinical research. A serum marker which can differentiate between haemorrhagic and ischaemic stroke in the very early phase would help to ...

Glioblastoma is a common brain tumor that poses considerable challenges in drug delivery. In this study, we investigated the potential of cell-based nanoparticles for targeted drug delivery to the ...

As the most common malignant brain tumors, glioblastoma multiforme (GBM) was characterized by angiogenesis and tumor cells proliferation. Dual targeting to neovasculature and GBM cells could deliver ...

1 Introduction. Glioblastoma (GBM) is the most common primary malignant tumor of the brain and central nervous system. It accounts for 14.5% of all central nervous system tumors and 48.6% of malignant ...

We searched PubMed for studies on plasma glial fibrillary acidic protein (GFAP) and MRI in patients with traumatic brain injury (TBI) published in English up to Nov 1, 2018, with the search terms ...

Their findings were published in the current issue of Science Signaling. (Link is external) Glioblastoma is an incurable cancer with an average survival time after diagnosis of around 12-18 months, ...

The one responder -- out of 18 patients with a diagnosis of GBM and EGFR amplification who had CAR T-cells injected into the cerebral ventricles to reach the cerebrospinal fluid (CSF) -- had a ...

IN8bio, Inc. announced promising new long-term results from its Phase 1 trial of INB-200, a treatment for newly diagnosed glioblastoma multiforme (GBM), during the ASCO Annual Meeting.

The genetic makeup and structure of glioblastoma tumors can shift dramatically across different regions of a single tumor, according to a Northwestern Medicine study published in Science Advances.

The study was published as a paper in Nature Medicine, titled “ Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a Phase I trial,” and ...

CHICAGO — New data on two studies are bolstering hopes that CAR-T therapy, which uses engineered immune T cells to fight cancer, may be able to overcome one of the most difficult to treat ...

a,b, Immunohistochemical staining of mouse GBM induced by Ras and Akt stained with antibody to Gfap and nestin, respectively. c,d, Immunohistochemical staining with antibodies to K-Ras and virally ...